STOCK TITAN

Disc Medicine Inc - IRON STOCK NEWS

Welcome to our dedicated news page for Disc Medicine (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Disc Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Disc Medicine's position in the market.

Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) receives Fast Track Designation from the FDA for DISC-0974 in the treatment of NDD-CKD patients with anemia, showcasing potential for addressing unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) receives Orphan Drug Designation from the FDA for DISC-3405 in treating polycythemia vera, a rare hematologic disease. The designation signifies potential benefits and support for the ongoing Phase 1 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
clinical trial
-
Rhea-AI Summary
Disc Medicine, Inc. appoints Jean Franchi as Chief Financial Officer and promotes Jonathan Yu to Chief Operating Officer. Franchi brings over 30 years of finance leadership experience in biotech companies, and Yu has been involved in key business roles at the company. The company expresses excitement about important data read-outs for their programs in 2024 and the potential for late-stage development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
management
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the retirement of Chief Innovation Officer, Dr. Brian MacDonald, after a distinguished 28-year career. Dr. MacDonald will transition to become Chair of Disc’s Scientific Advisory Board. The company expressed gratitude for his leadership and contributions, with plans for him to continue leading as part of the Scientific Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
management
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) presented updated results from the phase 2 open-label BEACON study of bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, in patients with erythropoietic protoporphyria (EPP) as an oral presentation at the 65th ASH Annual Meeting. The data showed significant reductions in protoporphyrin IX (PPIX) > 40%, improvements in sunlight tolerance, and positive results from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
clinical trial
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) has announced data from initial dose cohorts of its ongoing phase 1b/2 study of DISC-0974, a monoclonal antibody designed to suppress hepcidin by inhibiting the hemojuvelin (HJV) co-receptor, in MF patients with anemia. The initial data demonstrated that treatment with DISC-0974 substantially decreased serum hepcidin, increased serum iron, and resulted in improvements in hemoglobin or reduced transfusion burden across a broad range of MF patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
clinical trial
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the issuance of patent No. 11,813,257 by the USPTO for methods of treating erythropoietic protoporphyrias (EPPs) with glycine transport inhibitors. The patent covers the use of bitopertin, a glycine transport inhibitor, in treating EPP or XLP, with an anticipated expiration in 2041. This further secures IP protection for bitopertin, demonstrating Disc's innovative approach to treating EPP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) reported the completion of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP), with data from all adult patients in BEACON to be presented at ASH 2023. Preliminary pharmacodynamic data from the ongoing phase 1b/2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia will also be presented. Additionally, they initiated a Phase 1 trial of DISC-3405, an anti-TMPRSS6 antibody, and received fast track designation by the FDA for the treatment of polycythemia vera (PV). Financial results for the third quarter ended September 30, 2023, were also reported, with cash and cash equivalents of $370.5 million, increased R&D and G&A expenses, and a net loss of $14.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
earnings
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announces participation in fireside chats at Stifel 2023 Healthcare Conference and presentations at Jefferies London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts available on ir.discmedicine.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
Disc Medicine Inc

Nasdaq:IRON

IRON Rankings

IRON Stock Data

1.60B
13.16M
13.17%
86.68%
5.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Watertown

About IRON

disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.